Results 351 to 360 of about 327,068 (394)

Mepolizumab for the treatment of severe eosinophilic asthma

American Journal of Health-System Pharmacy, 2017
Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils ...
Allen L. Wolford, Melissa F. Waineo, Shawna M. Cargill, Mara N. Poulakos   +3 more
openaire   +2 more sources

Eosinophils in the pathogenesis of paediatric severe asthma

Current Opinion in Allergy & Clinical Immunology, 2014
The importance and functional contribution of eosinophils to the pathogenesis of severe asthma was questioned when adult studies reported neutrophilic inflammation and Th17 cells were central to disease.Eosinophilic inflammation, atopic sensitization and airway remodelling are the hallmark features of severe asthma in children.
Clare M. Lloyd, Sejal Saglani
openaire   +3 more sources

RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response

Allergy. European Journal of Allergy and Clinical Immunology, 2022
R E FE R E N C E S 1. Zuberbier T, Aberer W, Asero R, et al. Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA2LEN ...
M. Kallieri, E. Zervas, E. Fouka, Konstantinos Porpodis, Marija Hadji Mitrova, E. Tzortzaki, M. Makris, Maria Ntakoula, A. Papaioannou, P. Lyberopoulos, K. Dimakou, S. Koukidou, S. Ampelioti, A. Papaporfyriou, K. Katsoulis, M. Kipourou, N. Rovina, K. Antoniou, S. Vittorakis, P. Bakakos, P. Steiropoulos, K. Markopoulou, Panteleimon Avarlis, Ιlias C. Papanikolaou, Miltiadis Markatos, E. Gaki, K. Samitas, K. Glynos, S. Papiris, D. Papakosta, N. Tzanakis, M. Gaga, K. Kostikas, S. Loukides   +33 more
semanticscholar   +1 more source

Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma

Journal of Asthma, 2022
Introduction Severe eosinophilic asthma (SEA) is associated with multiple exacerbations. Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to be correlated with the risk of exacerbations.
C. Menigoz, S. Dirou, A. Chambellan, D. Hassoun, A. Moui, A. Magnan, F. Blanc   +6 more
semanticscholar   +1 more source

Histamine, Basophils and Eosinophils in Severe Asthma

Clinical Science, 1979
1. Arterial and venous whole blood and plasma histamine concentrations and eosinophil and basophil counts were determined in five patients with acute severe asthma who had not previously received steroid therapy, in five who had been maintained on steroid therapy and in a control group of nine patients with acute non-respiratory illnesses.
S. J. Williams, W. H. Taylor, T. J. Charles, A. Seaton, Christine Bruce   +4 more
openaire   +3 more sources

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2013
In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year.
openaire   +3 more sources

Prognostic factors in severe eosinophilic asthma

Monitoring Airway Disease, 2018
Introduction: Uncontrolled Severe Eosinophilic Asthma (USEA) represents a challenging health problem. Characterize variables that predict poor control in this patients to will improve its management. The aim was identify the factors of poor control of severe eosinophilic asthma. Methodes: Were collected 78 patients of our Asthma Severe Unit.
Filipe Gonçalves Dos Santos Carvalho, Alicia Francoso Vicente, Maria Del Mar Martinez Colls, Marisa Rivera Ortún, Albert Roger, Eva Martinez Cáceres, Carlos Pollan Guisasola, Maria Basagaña Torrento, Carlos Martinez Rivera, Juan Ruiz Manzano, Aina Teniente, Clara Padró Casas   +11 more
openaire   +5 more sources

Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab

Clinical and Experimental Allergy
Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term remains unclear.
D. J. Jackson, Hassan Burhan, H. Rupani, Paul E. Pfeffer, I. Clifton, Shoaib Faruqi, J. Dhariwal, P. Patel, T. Morris, Joe Lipworth, Michael Watt, C. Lupton, S. Dube, J. Hickey, A. Nanzer   +14 more
semanticscholar   +1 more source

Mepolizumab for eosinophilic severe asthma: recent studies

Expert Opinion on Biological Therapy, 2015
In September 2014 two large clinical studies of the anti-IL-5 monoclonal antibody mepolizumab in severe asthma were published in the New England Journal of Medicine (MENSA and SIRIUS).Eosinophilic inflammation has long been recognised as a feature of asthma.
Harsha H Kariyawasam, Douglas S Robinson
openaire   +3 more sources

Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2016
Asthma affects over 300 million people worldwide and is severe in 10% of sufferers. Severe asthma is associated with greater morbidity and mortality particularly as a consequence of frequent exacerbations. Advances in approaches to phenotype the heterogeneity of severe asthma has established the importance of eosinophilic inflammation and emerging new ...
Christopher E. Brightling, Richard J. Russell   +1 more
openaire   +3 more sources